A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
← catalyst calendarNCT06666335 · readout in 376 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With Tigermed Consulting Co., Ltd.
Phase
Phase 4
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-01 | estimated | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Familial Mediterranean Fever (FMF )
Intervention
- Drug: Anakinra — also filed as Kineret
Primary outcome
what the primary-completion date above is the date OFChange from baseline in the number of FMF attacks per month.
measured Up to 6 Months
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed